The radioimmunotherapy in lymphoma
PDF (Język Polski)

Keywords

non-Hodgkin lymphomas
oncology
radioimmunotherapy

How to Cite

Kuta, M., & Pietrzak, A. (2020). The radioimmunotherapy in lymphoma. Letters in Oncology Science, 17(2), 1-7. https://doi.org/10.21641/los.2020.17.2.181

Abstract

Radioimmunotherapy (RIT) is a targeted therapy combining radiobiological and immunological characteristics. RIT has been considered effective in terms of B-cell non-Hodgkin's lymphomas (NHL) treatment and it can be used as the main therapy or as the element of the combined RIT and chemotherapy. Despite RIT’s effectiveness in NHL therapy, it is still rarely used.

https://doi.org/10.21641/los.2020.17.2.181
PDF (Język Polski)

References

Dostęp w Internecie: Globocan 2018, Cancer Fact Sheets. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2018). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. http://gco.iarc. https://gco.iarc.fr/today. Data ostatniej aktualizacji: 01.1.2020.

Younes A. Handbook of Lymphoma. Springer, 2016. ISBN 978-3-319-08467.

Evans A M, Blum K A, Non-Hodgkin Lymphoma. Patology, Imaging and Current Therapy. Springer, 2015. ISBN 978-3-319-13150-4.

Marcus R, Sweetenham J W, Williams M. Lymphoma. Pathology, Diagnosis and Treatment. Second Edition. Cambridge, Cambridge University Press, 2014.

ISBN 978-1-107-01059-8.

Cheson B D, Fisher R I, Barrington S F. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma:

The Lugano Classification. Clin. Oncol. 2014; 32: 3059–3068.

Swerdlow S H, Campo E, Harris N L. WHO Classification of Tumours of Haematopoietic nad Lymphoid Tissues. Revised 4th Edition. Lyon, IARC, 2016. ISBN 978-92-835-4494-3.

Sachpekidis C, Jackson D B, Soldatos T G. Radioimmunotherapy in Non-Hodgkin’s Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar. Pharmaceuticals 2019, 12(4), 141.

Huang G. Nuclear Medicine in Oncology. Molecular Imaging and Target Therapy. Springer, 2019. ISBN 978-981-13-7458-6.

Giovanella L. Nuclear Medicine Therapy. Side Effects and Complications. Springer, 2019. ISBN 978-3-030-17494-1.

Schlechter B L, Kim M S, Joyce R M. An update on radioimmunotherapy for lymphoma. J. Hematol. Oncol 2013, 2(2), 163–178.

Aktolun C, Goldsmith S J. Nuclear Medicine Therapy. Principles and Clinical Applications. Springer, 2013. ISBN 978-1-4614-4021-5.

Schimoni A, Zwas S T. Radioimmunotherapy and Autologous Stem-Cell Transplantation in the Treatment of B-Cell Non-Hodgkin Lymphoma. Seminars in nuclear medicine 2016, 46(2):119-125.

Bombardieri E, Seregni E, Evangelista L, Chiesa C, Chiti A. Clinical Applications of Nuclear Medicine Targeted Therapy. Springer 2018. ISBN 978-3-319-63067-0.

Eskian M, Khorasanizadeh M, Zinzani M P, Rezaei N. Radioimmunotherapy as the first line of treatment in non-Hodgkin lymphoma. Immunotherapy 2018; 10(8):

-711.

Regan P M, Friedberg J W. Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma. Future Oncology 2015, 11(10):1543-53.

Kitajima K, Okada M, Kashiwagi T, Yoshihara K, Tokugawa T , Sawada A, Yoshihara S, Fujimori Y, Yamakado K. Early evaluation of tumor response to

Y-ibritumomab radioimmunotherapy in relapsed/refractory B cell non-Hodgkin lymphoma: what is the optimal timing for FDG-PET/CT?. Europen Radiology 2019, 29(7):3935-3944.

Repetto‐Llamazares A H V, Malenge M M, O'Shea A, Eiríksdóttir B, Stokke T, Larsen R H, Dahle J. Combination of 177Lu‐lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non‐Hodgkin's lymphoma.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

Downloads

Download data is not yet available.